The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Comparing Alectinib Versus Crizotinib in ALK+ NSCLC

David R. Gandara, MD
Published Online:5:18 PM, Mon November 13, 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses results of the ALEX clinical trial, which compared alectinib (Alecensa) versus crizotinib (Xalkori) in patients with ALK+ non–small cell lung cancer (NSCLC).
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.